Midatech Pharma Stock Scheduled to Reverse Split on Monday, March 27th (NASDAQ:MTP)

Midatech Pharma plc (NASDAQ:MTP – Get Rating) shares are going to reverse split before the market opens on Monday, March 27th. The 1-4 reverse split was announced on Monday, March 27th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, March 27th.

Midatech Pharma Stock Up 6.1 %

MTP opened at $0.36 on Friday. The business’s 50 day moving average is $0.60 and its 200-day moving average is $1.44. Midatech Pharma has a twelve month low of $0.33 and a twelve month high of $5.25.

Institutional Investors Weigh In On Midatech Pharma

A hedge fund recently bought a new stake in Midatech Pharma stock. Armistice Capital LLC purchased a new stake in shares of Midatech Pharma plc (NASDAQ:MTP – Get Rating) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 386,828 shares of the company’s stock, valued at approximately $381,000. Armistice Capital LLC owned about 1.79% of Midatech Pharma at the end of the most recent quarter. 4.21% of the stock is currently owned by institutional investors and hedge funds.

About Midatech Pharma

(Get Rating)

Midatech Pharma Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm’s proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale.